Last updated: August 27, 2026
Meclizine hydrochloride is a mature, low-cost antihistamine used for motion sickness and vertigo. The active ingredient has no meaningful composition-of-matter exclusivity remaining. Commercial value is concentrated in formulation convenience, taste masking, rapid disintegration, channel access, private-label supply, and differentiated packaging rather than core-drug patents.
The strongest opportunities are chewable tablets, orally disintegrating tablets, low-moisture formulations, travel-oriented packaging, and combination products that comply with applicable FDA monograph or OTC regulatory requirements.
What is the FDA regulatory status of meclizine hydrochloride?
Meclizine is marketed in prescription and over-the-counter products in the United States.
| Attribute |
Status |
| Active ingredient |
Meclizine hydrochloride |
| Main uses |
Motion sickness; symptomatic treatment of vertigo associated with vestibular disease |
| Common strength |
25 mg |
| Dosage forms |
Conventional tablets, chewable tablets, orally disintegrating or rapidly dissolving products |
| Prescription brand |
Antivert |
| OTC brands |
Bonine, Dramamine Less Drowsy and private-label products |
| FDA pathway |
Approved prescription products and OTC marketing under the applicable FDA monograph framework |
| Pediatric labeling |
Generally directed to adults and children 12 years and older for common OTC products |
| Biosimilar exposure |
None |
| Core-drug exclusivity |
Expired |
| Primary commercial barriers |
Brand recognition, retail placement, formulation execution, supply reliability and regulatory compliance |
The FDA’s Drugs@FDA database identifies legacy approved meclizine products, while FDA OTC monograph materials govern applicable nonprescription motion-sickness products. Product-specific labeling controls dosage, age restrictions, warnings and administration instructions.[1,2]
Meclizine is a first-generation antihistamine. Sedation, dry mouth, blurred vision and impaired alertness are relevant labeling and commercial considerations. A formulation that improves taste or convenience does not remove those pharmacologic limitations.
What patents protect meclizine hydrochloride products?
No active composition-of-matter patent should be expected to protect meclizine hydrochloride. The molecule was commercialized decades ago, and generic and private-label products are widely available.
The relevant patent categories are narrower:
| Patent category |
Commercial relevance |
Current risk assessment |
| Meclizine composition patent |
Covers the active molecule or salt |
No meaningful remaining exclusivity expected |
| Basic tablet formulation |
Covers conventional excipient combinations or manufacturing steps |
Low barrier; design-around generally feasible |
| Chewable formulation |
May cover taste masking, granulation or compression parameters |
Potentially relevant only if a live patent is identified |
| Orally disintegrating tablet |
May cover porous matrix, particle engineering or taste masking |
Moderate product-specific risk |
| Combination product |
May cover meclizine with another active ingredient |
Depends on the specific combination and claims |
| Method of treatment |
May cover a narrowly defined indication, dose or patient population |
Limited relevance for ordinary OTC motion-sickness use |
| Manufacturing process |
May cover crystallization, particle size or purification |
Usually avoidable through alternate process conditions |
An Orange Book listing does not automatically establish a broad barrier to a new meclizine product. Orange Book-listed patents are tied to specific approved products and claims. The Orange Book must be reviewed at the product level before filing an ANDA or pursuing an abbreviated regulatory strategy.[3]
When does meclizine hydrochloride lose exclusivity?
Meclizine hydrochloride has already lost ordinary small-molecule exclusivity. The commercial question is not when generic entry begins. Generic entry has already occurred.
The practical exclusivity timeline is:
| Period |
Market event |
| 1950s and 1960s |
Meclizine developed and commercialized |
| Later prescription lifecycle |
Antivert and other prescription products established the vertigo market |
| OTC commercialization |
Meclizine became available in nonprescription motion-sickness products |
| Current market |
Multiple branded, generic and private-label products compete |
| Future opportunity |
Differentiation through dosage form, taste, packaging, supply and channel economics |
There is no expected biosimilar pathway because meclizine is a chemically synthesized small molecule, not a biologic. The applicable competition is generic, OTC monograph, NDA, or product-specific reformulation competition.
How many patents cover meclizine hydrochloride?
No meaningful number of active, broad patents can be assigned without a current patent-family and jurisdictional search. The defensible commercial conclusion is that the core molecule is off-patent and any remaining rights would likely relate to a particular formulation, process, combination or use.
A diligence review should separate:
- Active U.S. patents from expired patents.
- Granted claims from pending applications.
- Product-specific Orange Book listings from unrelated patent families.
- U.S. rights from patents that remain active in Canada, Europe, Japan, China or other markets.
- Broad composition claims from narrow manufacturing or dosage-form claims.
Patent expiry should be calculated family by family. Priority date, patent-term adjustment, terminal disclaimers, patent-term extension and maintenance status can change the effective date. A publication or abandoned application does not create a continuing blocking right.
What excipients are best for meclizine hydrochloride tablets?
The most practical platform is an immediate-release compressed tablet using a robust filler-binder, a superdisintegrant and a low-level lubricant.
| Formulation function |
Suitable excipient classes |
Commercial purpose |
| Diluent |
Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate |
Tablet size, compressibility and cost control |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Granule strength and tablet robustness |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Faster breakup after administration |
| Glidant |
Colloidal silicon dioxide |
Powder flow and weight uniformity |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Ejection and manufacturing reliability |
| Film coating |
Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants |
Appearance, swallowability and brand differentiation |
| Sweetener |
Sucralose, acesulfame potassium, saccharin or sugar alcohols |
Taste improvement for chewables and ODTs |
| Flavor |
Mint, fruit or neutral flavor systems |
Masking of bitter or medicinal taste |
| Moisture control |
Desiccant packaging, high-barrier blister, low-water excipient system |
Stability and shelf-life protection |
Mannitol is attractive for chewable and orally disintegrating formats because it provides a cooling mouthfeel and acceptable compressibility. Microcrystalline cellulose is useful where mechanical strength and rapid disintegration are priorities. Lactose can reduce cost but may create labeling and formulation constraints for lactose-sensitive consumers.
Magnesium stearate should be optimized rather than used at excessive levels. Over-lubrication can slow wetting and dissolution. Sodium stearyl fumarate can be evaluated when faster disintegration or improved lubricant performance is required.
What formulation strategy is strongest for a meclizine chewable tablet?
A chewable tablet is the most commercially accessible differentiation route. It can target travelers, patients who dislike swallowing tablets and consumers seeking a portable product.
A viable chewable platform would use:
- Mannitol or a mannitol-cellulose blend as the principal filler.
- A low level of microcrystalline cellulose or silicified microcrystalline cellulose for structure.
- Crospovidone or croscarmellose sodium for breakup.
- Sucralose or another high-intensity sweetener for potency control.
- A compatible flavor system, commonly mint, fruit or a neutralizing flavor.
- A low-moisture manufacturing process.
- Blister packaging or a tightly sealed bottle with desiccant.
Taste masking is the central technical issue. Meclizine is potent at a relatively low dose, so the excipient burden can be used to create a pleasant mouthfeel. The formulation should be evaluated for:
- Initial bitterness.
- Aftertaste duration.
- Grittiness.
- Tablet fracture during chewing.
- Moisture uptake.
- Flavor migration during stability testing.
- Dissolution after prolonged storage.
A sugar-free product can broaden the retail proposition, but polyols such as sorbitol or mannitol may create gastrointestinal tolerance concerns at higher quantities. A low-sugar or sugar-free claim must be supported by the finished formulation and labeling.
What excipients are suitable for an orally disintegrating meclizine tablet?
An ODT can create a stronger convenience proposition than a standard tablet, but it has a narrower technical design space.
Suitable excipient systems include:
- Mannitol for mouthfeel and rapid dissolution.
- Crospovidone or croscarmellose sodium for disintegration.
- Low-substituted hydroxypropyl cellulose where structural support is needed.
- Microcrystalline cellulose in controlled amounts.
- Colloidal silicon dioxide for flow.
- Taste-masking polymers or coated API particles.
- High-intensity sweeteners and flavors.
- Low-moisture packaging.
The ODT must balance three competing requirements: rapid oral dispersion, sufficient tablet strength and acceptable taste. A porous tablet that disintegrates rapidly may be more fragile during bottling and transportation. A stronger tablet may dissolve more slowly or leave a gritty residue.
A proprietary opportunity may exist in coated meclizine particles, ion-exchange resin complexes, lipid-based taste masking or a multiparticulate ODT. Those approaches can support formulation patents, but they also increase manufacturing complexity and cost.
What manufacturing and intellectual-property barriers affect meclizine products?
Manufacturing barriers are modest for conventional tablets and higher for taste-masked or rapidly disintegrating formats.
Conventional tablets
Direct compression is attractive when the API and excipients have compatible flow and compressibility. Wet granulation can improve content uniformity and tablet strength but adds drying, moisture and scale-up steps.
Key controls include:
- API particle-size distribution.
- Blend uniformity.
- Segregation during transfer.
- Lubrication time.
- Tablet hardness and friability.
- Disintegration and dissolution.
- Residual moisture.
- Assay and content uniformity.
Chewables and ODTs
These products require tighter control of:
- Flavor uniformity.
- API coating efficiency.
- Tablet friability.
- Compression force.
- Ejection defects.
- Moisture ingress.
- Packaging seal integrity.
- Consumer acceptability.
A formulation patent may be avoidable through changes in polymer, coating level, excipient ratio, compression conditions or manufacturing sequence. Process patents can be more relevant where particle engineering or specialized coating equipment is required.
What Orange Book status applies to meclizine hydrochloride?
Meclizine products should be assessed individually because prescription and OTC products do not have identical regulatory treatment.
The Orange Book is most relevant to approved prescription products and patent certifications associated with listed products. An applicant considering an ANDA should review:
- The selected reference listed drug.
- Any listed patents.
- Pediatric exclusivity.
- Product-specific exclusivity.
- Dosage-form and strength matching.
- Labeling differences.
- Paragraph I, II, III or IV certification requirements.
For an old meclizine product, the expected commercial pathway is usually a low-risk patent certification strategy because broad patent protection has expired. The principal regulatory risk is product selection and labeling, not loss of core-drug exclusivity.
Which companies are challenging meclizine products?
Meclizine is already exposed to broad generic and private-label competition. The market includes branded OTC products, retailer-controlled brands, generic manufacturers and contract manufacturers.
The competitive set is less defined by Paragraph IV litigation than by:
- Retail shelf placement.
- Pharmacy and grocery private-label contracts.
- E-commerce ranking.
- Unit economics.
- Packaging formats.
- Product reviews and consumer recognition.
- Reliable API and finished-dose supply.
No biosimilar challengers are relevant. A Paragraph IV strategy would be relevant only against a live patent covering a specific formulation or combination product. For ordinary meclizine tablets, the commercial case does not depend on challenging an active core patent.
What patent litigation affects meclizine hydrochloride?
No major current litigation should be assumed to block a conventional meclizine hydrochloride tablet. The relevant litigation risk would arise from:
- A formulation patent listed against a specific reference product.
- A patent covering an ODT or taste-masked dosage form.
- A combination product with a newer active ingredient.
- A trademark or trade-dress dispute involving packaging or brand presentation.
- A supplier dispute over API specifications or manufacturing rights.
A Paragraph IV notice would require a product-specific assessment under the Hatch-Waxman framework. The existence of a patent application or an expired formulation patent would not by itself create launch risk.
What licensing deals exist for meclizine hydrochloride?
The molecule is sufficiently mature that licensing value is likely to arise from commercial assets rather than the active ingredient. Potentially valuable deal structures include:
| Deal type |
Likely asset |
| Brand licensing |
Consumer brand, trademark and retail presence |
| Private-label supply |
Finished-dose manufacturing and retailer distribution |
| Formulation licensing |
ODT, chewable, taste-masked or extended-release technology |
| Geographic licensing |
Country-specific registration and distribution rights |
| API supply agreement |
Qualified source, capacity reservation and quality package |
| Combination-product licensing |
Meclizine with another active ingredient or delivery technology |
There is no apparent need to license basic meclizine chemistry for a standard tablet. A formulation license would make sense only if it delivers measurable advantages in taste, disintegration, stability, patient adherence or manufacturing cost.
What are the best commercial opportunities for meclizine hydrochloride?
1. Private-label chewable tablets
Retailers can use a 25 mg chewable product to differentiate from ordinary generic tablets. The product can be positioned for travel, cruise use, amusement parks and occasional motion sickness.
2. Orally disintegrating tablets
An ODT can command a modest premium if it has acceptable taste, low friability and reliable rapid disintegration. Packaging quality is critical.
3. Travel packs
Small-count blister packs can support airport, convenience-store and e-commerce sales. Claims should remain within approved labeling.
4. Premium packaging
Unit-dose blisters, child-resistant formats and moisture-protective packaging can support higher margins without changing the active ingredient.
5. Global market expansion
Regulatory status varies by country. A product approved as prescription-only in one jurisdiction may be nonprescription in another. Local monographs, language requirements, age restrictions and permitted excipients must be reviewed country by country.
6. Contract manufacturing
The mature active ingredient creates opportunities for reliable, low-cost manufacturing. The strongest contract-manufacturing proposition would combine qualified API sourcing, low minimum order quantities, flexible packaging and retail-ready documentation.
How strong is the meclizine hydrochloride patent estate?
The core patent estate is weak because the molecule is old and generic competition is established. A new formulation estate could be moderately strong if it has:
- Narrow but enforceable claims tied to a defined dosage form.
- Demonstrated taste-masking performance.
- Unexpected stability or dissolution results.
- A manufacturing process that is difficult to reproduce.
- Commercially important packaging or delivery features.
- Claims that avoid unnecessary limitation to one excipient supplier.
A conventional tablet using standard excipients is unlikely to support durable patent differentiation. Regulatory exclusivity may be available for a genuinely new product or indication, but it would not restore exclusivity to the underlying meclizine molecule.
What revenue exposure exists for meclizine products?
Public company filings generally do not isolate meclizine revenue from broader OTC or generic portfolios. Revenue exposure should therefore be modeled through units, net price and channel mix rather than reported product sales.
A practical model is:
| Variable |
Key driver |
| Volume |
Motion-sickness seasonality, travel activity and retail distribution |
| Net price |
Standard tablet versus chewable or ODT premium |
| Gross margin |
API cost, packaging, conversion cost and retailer deductions |
| Working capital |
Inventory requirements and seasonal demand |
| Risk |
Retailer concentration, API shortages, recalls and price competition |
| Upside |
Private-label contracts, new dosage forms and international registration |
The largest financial risk is price compression in standard tablets. The best margin opportunity is a differentiated dosage form with protected taste-masking or delivery technology and strong retail placement.
Key Takeaways
- Meclizine hydrochloride is a mature, off-patent small molecule.
- No biosimilar risk exists; competition is generic, OTC and private-label.
- Conventional tablets have limited patent and pricing power.
- Chewable and ODT products offer the clearest commercial differentiation.
- Mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, sweeteners and flavors are practical excipient platforms.
- Taste masking, moisture control and tablet robustness are the main technical challenges.
- Orange Book and Paragraph IV analysis must be performed against the specific reference product and formulation.
- Licensing value is more likely to arise from formulation technology, brands, manufacturing capacity or geographic rights than from meclizine chemistry.
- Revenue modeling should focus on units, channel access, dosage-form premium and private-label contracts.
FAQs
Is meclizine hydrochloride still patent protected?
The underlying molecule is not expected to have active composition-of-matter protection. Product-specific formulation or process patents require separate review.
Can meclizine be developed as a pediatric liquid?
A pediatric liquid would require careful assessment of age-specific labeling, dosing, palatability, preservative selection, chemical stability and applicable FDA requirements. Common OTC labeling is generally directed to individuals 12 years and older.
What is the most defensible meclizine formulation patent strategy?
A patent strategy focused on taste-masked particles, rapid oral dispersion, moisture stability or a defined manufacturing process is more defensible than a conventional tablet using standard excipients.
Is meclizine suitable for a combination product?
It may be technically suitable, but the combination would require an indication, dosing rationale, safety review and regulatory pathway that justify the added complexity. Combination claims may create new patent opportunities but also increase litigation and labeling risk.
Which packaging format best supports a premium meclizine product?
Unit-dose high-barrier blister packaging is well suited to travel-oriented products and can improve portability, moisture protection and dose control. References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.accessdata.fda.gov/scripts/cder/otc/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Meclizine hydrochloride prescribing information and labeling records. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Electronic Code of Federal Regulations. (n.d.). Title 21, Food and drugs. https://www.ecfr.gov/current/title-21
